Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

194 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-Term Survival in Gastroesophageal Junction Adenocarcinoma: Ramucirumab.
Gil-Delgado MA, Lucidarme O, Bachet JB, Mahi N, Khayat D. Gil-Delgado MA, et al. Among authors: bachet jb. Case Rep Gastroenterol. 2018 Aug 31;12(2):532-539. doi: 10.1159/000490906. eCollection 2018 May-Aug. Case Rep Gastroenterol. 2018. PMID: 30283289 Free PMC article.
Real time identification of drug-induced liver injury (DILI) through daily screening of ALT results: a prospective pilot cohort study.
M'Kada H, Perazzo H, Munteanu M, Ngo Y, Ramanujam N, Fautrel B, Imbert-Bismut F, Ratziu V, Schuppe-Koistinen I, Leblond V, Delattre JY, Samson Y, Caen OL, Bricaire F, Khayat D, Pierrot-Deseilligny C, Herson S, Amoura Z, Tilleul P, Deckmyn O, Coriat P, Delpech VN, Boulogne P, Bonnefont-Rousselot D, Poynard T; Drug Induced Liver Injury Groupe Hospitalier Pitié-Salpêtrière Group; Safer and Faster Evidence-based Translation Consortium. M'Kada H, et al. PLoS One. 2012;7(8):e42418. doi: 10.1371/journal.pone.0042418. Epub 2012 Aug 14. PLoS One. 2012. PMID: 22905129 Free PMC article.
RECIST and CHOI criteria in the evaluation of tumor response in patients with metastatic colorectal cancer treated with regorafenib, a prospective multicenter study.
Lucidarme O, Wagner M, Gillard P, Kim S, Bachet JB, Rousseau B, Mazard T, Louvet C, Chibaudel B, Cohen R, Garcia-Larnicol ML, Gobert A, Henriques J, André T. Lucidarme O, et al. Among authors: bachet jb. Cancer Imaging. 2019 Dec 9;19(1):85. doi: 10.1186/s40644-019-0271-z. Cancer Imaging. 2019. PMID: 31818317 Free PMC article.
Impact of trough concentrations of regorafenib and its major metabolites M-2 and M-5 on overall survival of chemorefractory metastatic colorectal cancer patients: Results from a multicentre GERCOR TEXCAN phase II study.
Rousseau B, Boukerma AK, Henriques J, Cohen R, Lucidarme O, Borg C, Tournigand C, Kim S, Bachet JB, Mazard T, Louvet C, Chibaudel B, Vernerey D, Andre T, Hulin A. Rousseau B, et al. Among authors: bachet jb. Eur J Cancer. 2022 Jun;168:99-107. doi: 10.1016/j.ejca.2022.03.009. Epub 2022 Apr 27. Eur J Cancer. 2022. PMID: 35489233 Free PMC article. Clinical Trial.
Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial.
Bachet JB, Hammel P, Desramé J, Meurisse A, Chibaudel B, André T, Debourdeau P, Dauba J, Lecomte T, Seitz JF, Tournigand C, Aparicio T, Meyer VG, Taieb J, Volet J, Monier A, Bonnetain F, Louvet C. Bachet JB, et al. Lancet Gastroenterol Hepatol. 2017 May;2(5):337-346. doi: 10.1016/S2468-1253(17)30046-8. Epub 2017 Feb 28. Lancet Gastroenterol Hepatol. 2017. PMID: 28397697 Clinical Trial.
Characteristic and outcomes of patients with pathologic complete response after preoperative treatment in borderline and locally advanced pancreatic adenocarcinoma: An AGEO multicentric retrospective cohort.
Kourie H, Auclin E, Cunha AS, Gaujoux S, Bruzzi M, Sauvanet A, Lourenco N, Trouilloud I, Louafi S, El-Hajjar A, Vaillant JC, Smith D, Touchefeu Y, Bachet JB, Pietrasz D, Taieb J. Kourie H, et al. Among authors: bachet jb. Clin Res Hepatol Gastroenterol. 2019 Nov;43(6):663-668. doi: 10.1016/j.clinre.2019.03.007. Epub 2019 Apr 24. Clin Res Hepatol Gastroenterol. 2019. PMID: 31029644
FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial.
Malka D, François E, Penault-Llorca F, Castan F, Bouché O, Bennouna J, Ghiringhelli F, de la Fouchardière C, Borg C, Samalin E, Bachet JB, Raoul JL, Miglianico L, Bengrine-Lefèvre L, Dahan L, Lecaille C, Aparicio T, Stanbury T, Perrier H, Cayre A, Laurent-Puig P, Gourgou S, Emile JF, Taïeb J. Malka D, et al. Among authors: bachet jb. Eur J Cancer. 2019 Jul;115:97-106. doi: 10.1016/j.ejca.2019.04.020. Epub 2019 May 23. Eur J Cancer. 2019. PMID: 31129386 Clinical Trial.
Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: a retrospective study.
Soularue É, Cohen R, Tournigand C, Zaanan A, Louvet C, Bachet JB, Hentic O, Samalin E, Chibaudel B, de Gramont A, André T; for GERCOR. Soularue É, et al. Among authors: bachet jb. Bull Cancer. 2015 Apr;102(4):324-31. doi: 10.1016/j.bulcan.2014.08.001. Epub 2015 Mar 3. Bull Cancer. 2015. PMID: 25744576
194 results